The Nai-Kong Cheung Lab: Publications

The Nai-Kong Cheung Lab: Publications

Share
Print
Share
Print

View a full listing of Nai-Kong V. Cheung’s journal articles.


Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ.  Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.  Lancet Oncol. 2018 Jun 15. pii: S1470-2045(18)30322-X. doi: 10.1016/S1470-2045(18)30322-X.

Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK.  Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma – A Phase 1 Clinical Trial.  JAMA Oncol. 2018 September 20. doi:10.1001/jamaoncol.2018.4005

Hoseini SS, Guo HF, Wu ZH, Hatano MN, Cheung NKV.  A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.  Blood Advances 2(11):1250-1258, 2018

Wu ZH, Guo HF, Xu H, Cheung NKV.  Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers. Mol Cancer Ther. 2018 Aug 6. pii: molcanther.0026.2018. doi: 10.1158/1535-7163.MCT-18-0026.

Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P, Hasan AH, Selvakumar A, O’Reilly RJ, Liu C, Cheung NKV.  TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018 Feb 22;3(4). pii: 97805. doi: 10.1172/jci.insight.97805.

Wu ZH, Cheung NKV.  T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics.  Pharmacology & Therapeutics, Pharmacol Ther. 2018 Feb;182:161-175

Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NKV, Larson SM.  Curative multi-cycle radioimmunotherapy monitored by quantitative SPECT/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer.  Journal of Nuclear Medicine 58(11):1735-1742, 2017.

Hoseini SS, Dobrenkov K, Pankov D, Xu XL, and Cheung NK. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.  Oncoimmunology. 2017;6(6):e1320625. 

Lopez-Albaitero A, Xu H, Guo HF, Wang LL, Wu Z, Tran H, Chandarlapaty S, Scaltriti M, Janjigian Y, de Stanchina E, and Cheung NK.  Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. OncoImmunology 2017 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017.

Xu H, Guo HF, Cheung IY, Cheung NK.  Antitumor efficacy of anti-GD2 IgG1 is enhanced by Fc glyco-engineering.  Cancer Immunol Res 4:631-638, 2016.

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O’Reilly RJ and Cheung NK. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.  Leukemia;29(11):2238-2247, 2015.

Zhao Q, Ahmed M, Guo HF, Cheung IY, and Cheung NK.  Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. Journal of Biological Chemistry 290:13017-13027, 2015.

Ahmed M, Cheng M, Zhao Q, Yehuda G, Cheal SM, Guo HF, Larson SM, and Cheung NK. Humanized Affinity-Matured Monoclonal Antibody 8H9 Has Potent Anti-Tumor Activity and Binds to FG Loop of B7-H3. Journal of Biological Chemistry 290(50):30018-30029, 2015.

Larson SM, Carrasquillo JA, Cheung NK, Press O. Radioimmunotherapy of human tumours. Nature Reviews Cancer 15:347-360, 2015.

Xu H, Cheng M, Guo HF, Chen Y, Huse M, Cheung NK. Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody. Cancer Immunol Res. 2015 Mar;3(3):266-77.

Cheung NK and Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature Reviews Cancer 13:397-411, 2013.